Portland, Oregon — March 4, 2026 — Leads & Copy — Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced its nPulse technology will be featured at the Annual North American Society for Interventional Thyroidology 2026 meeting, scheduled for March 6-7 in Portland, Oregon. The nPulse technology utilizes the company’s proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy.
Paul LaViolette, Co-Chairman of Pulse Biosciences’ Board of Directors, expressed pleasure in sharing long-term follow-up data for patients treated in the nPulse Vybrance feasibility study. Patients have been followed for up to 22 months. LaViolette thanked Prof. Stefano Spieza, the team at Ospedale del Mare in Naples, Italy, and the nPulse Vybrance investigators for their work in advancing the treatment of benign thyroid nodules with nsPFA technology. He also mentioned the company looks forward to engaging with the clinical community at the meeting, while acknowledging that further work and analysis are needed.
The nPulse Technology Scientific Programming includes two key events:
On Friday, March 6th, at 4:40pm, Prof. Stefano Spiezia will present during the Clinical Science Session. His presentation is titled: “Interim Report: Clinical Feasibility Study of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation – Durability of Volume and Symptom Reduction”. The presentation will review the long-term follow up at 15-22 months for patients treated in the initial feasibility study of nPulse Vybrance technology used for the ablation of benign, symptomatic thyroid nodules.
On Saturday, March 7th, a Product Theatre Presentation will take place from 7:00-7:45am, featuring Ralph Tufano, MD, Prof. Stefano Spiezia, Emad Kandil, MD, and Kepal Patel, MD. The presentation is titled: “nPulse Technology – the Potential of Nonthermal Ablation with nsPFA Energy is a work in process”. This roundtable presentation will be led by top nPulse users, who will discuss the technology, its mechanism of action, results, and case studies of the use of nPulse Vybrance technology for benign, symptomatic thyroid nodules.
Pulse Biosciences is described as a bioelectric medicine company focused on health innovation to improve patients’ quality of life. The company’s nPulse™ technology delivers nanosecond pulses of electrical energy to clear cells non-thermally while sparing adjacent noncellular tissue. The company is developing its nPulse technology for use in treating atrial fibrillation and for surgical soft tissue ablation.
Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are trademarks and/or registered trademarks of Pulse Biosciences, Inc.
Source: Pulse Biosciences
